Cargando…
Selegiline: a molecule with innovative potential
Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242272/ https://www.ncbi.nlm.nih.gov/pubmed/31562557 http://dx.doi.org/10.1007/s00702-019-02082-0 |
_version_ | 1783537209915211776 |
---|---|
author | Tábi, Tamás Vécsei, László Youdim, Moussa B. Riederer, Peter Szökő, Éva |
author_facet | Tábi, Tamás Vécsei, László Youdim, Moussa B. Riederer, Peter Szökő, Éva |
author_sort | Tábi, Tamás |
collection | PubMed |
description | Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on–off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson’s disease. However, the serious side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors. |
format | Online Article Text |
id | pubmed-7242272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-72422722020-06-03 Selegiline: a molecule with innovative potential Tábi, Tamás Vécsei, László Youdim, Moussa B. Riederer, Peter Szökő, Éva J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Review Article Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on–off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson’s disease. However, the serious side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors. Springer Vienna 2019-09-27 2020 /pmc/articles/PMC7242272/ /pubmed/31562557 http://dx.doi.org/10.1007/s00702-019-02082-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Neurology and Preclinical Neurological Studies - Review Article Tábi, Tamás Vécsei, László Youdim, Moussa B. Riederer, Peter Szökő, Éva Selegiline: a molecule with innovative potential |
title | Selegiline: a molecule with innovative potential |
title_full | Selegiline: a molecule with innovative potential |
title_fullStr | Selegiline: a molecule with innovative potential |
title_full_unstemmed | Selegiline: a molecule with innovative potential |
title_short | Selegiline: a molecule with innovative potential |
title_sort | selegiline: a molecule with innovative potential |
topic | Neurology and Preclinical Neurological Studies - Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242272/ https://www.ncbi.nlm.nih.gov/pubmed/31562557 http://dx.doi.org/10.1007/s00702-019-02082-0 |
work_keys_str_mv | AT tabitamas selegilineamoleculewithinnovativepotential AT vecseilaszlo selegilineamoleculewithinnovativepotential AT youdimmoussab selegilineamoleculewithinnovativepotential AT riedererpeter selegilineamoleculewithinnovativepotential AT szokoeva selegilineamoleculewithinnovativepotential |